SurModics in deal to develop sustained-release Lucentis
This article was originally published in Scrip
Executive Summary
Roche's subsidiary Genentech has obtained an exclusive licence to use SurModics' biodegradable microparticles drug delivery system to develop and commercialise a sustained drug delivery formulation of Lucentis (ranibizumab injection), the only US FDA-approved therapy for wet age-related macular degeneration.